Financial Relationships |
A. John Rush, M.D. |
(Last 5 Years) |
Commercial Interest |
What I Received |
My Role |
Advanced Neuromodulation Systems |
Consulting Fee |
Consultant |
AstraZeneca |
Consulting Fee |
Consultant |
Best Practice Project Management |
Consulting Fee |
Consultant |
Bristol-Myers Squibb/Otsuka |
Consulting Fee |
Consultant |
Cyberonics |
Consulting Fee/Honoraria |
Consultant/Speaker |
Forest Pharmaceuticals |
Consulting Fee/Honoraria |
Consultant/Speaker |
Gerson Lehrman Group |
Consulting Fee |
Consultant |
GlaxoSmithKline |
Consulting Fee/Honoraria |
Consultant/Speaker |
Guilford Publications |
Royalties |
Author |
Healthcare Technology Systems |
Royalties |
Author |
Jazz Pharmaceuticals |
Consulting Fee |
Consultant |
Magellan Health Services |
Consulting Fee |
Consultant |
Merck & Company |
Consulting Fee |
Consultant |
Neuronetics |
Consulting Fee |
Consultant |
National Institute of Mental Health |
Research Support |
Researcher |
Novartis Pharmaceuticals |
Consulting Fee |
Consultant |
Ono Pharmaceuticals |
Consulting Fee |
Consultant |
Organon |
Consulting Fee |
Consultant |
Otsuka Pharmaceuticals |
Consulting Fee |
Consultant/Speaker |
Pamlab |
Consulting Fee |
Consultant |
Pfizer |
Consulting Fee/Income |
Consultant/Stock Holder |
Society of Biological Psychiatry |
Stipend |
Treasurer |
Stanley Medical Research Institute |
Research Support |
Researcher |
Transcept Pharmaceuticals |
Consulting Fee |
Consultant |
Urban Institute |
Consulting Fee |
Consultant |
Wyeth Ayerst |
Consulting Fee |
Consultant |